These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M; Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105 [TBL] [Abstract][Full Text] [Related]
8. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683 [TBL] [Abstract][Full Text] [Related]
9. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment. Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056 [TBL] [Abstract][Full Text] [Related]
10. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956 [TBL] [Abstract][Full Text] [Related]
11. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494 [TBL] [Abstract][Full Text] [Related]
12. Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. Nedelska Z; Schwarz CG; Lesnick TG; Boeve BF; Przybelski SA; Lowe VJ; Kremers WK; Gunter JL; Senjem ML; Graff-Radford J; Ferman TJ; Fields JA; Knopman DS; Petersen RC; Jack CR; Kantarci K JAMA Netw Open; 2019 Dec; 2(12):e1916439. PubMed ID: 31790563 [TBL] [Abstract][Full Text] [Related]
13. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ; Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606 [TBL] [Abstract][Full Text] [Related]
14. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study. Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T; Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127 [TBL] [Abstract][Full Text] [Related]
16. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden. Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551 [TBL] [Abstract][Full Text] [Related]
17. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI). de Rojas I; Romero J; Rodríguez-Gomez O; Pesini P; Sanabria A; Pérez-Cordon A; Abdelnour C; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Alegret M; Espinosa A; Ortega G; Gil S; Guitart M; Gailhajanet A; Santos-Santos MA; Moreno-Grau S; Sotolongo-Grau O; Ruiz S; Montrreal L; Martín E; Pelejà E; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MA; Giménez J; Pérez-Grijalba V; Marquié GM; Monté-Rubio G; Valero S; Orellana A; Tárraga L; Sarasa M; Ruiz A; Boada M; Alzheimers Res Ther; 2018 Nov; 10(1):119. PubMed ID: 30497535 [TBL] [Abstract][Full Text] [Related]
18. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040 [TBL] [Abstract][Full Text] [Related]
19. Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. Almkvist O; Brüggen K; Nordberg A J Alzheimers Dis; 2021; 81(4):1613-1624. PubMed ID: 33967046 [TBL] [Abstract][Full Text] [Related]
20. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]